We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

SEC Looks Into Dendreon Following FDA Disclosure

Law360 (July 10, 2007, 12:00 AM EDT) -- Biotechnology company Dendreon Corp. said Tuesday that the U.S. Securities and Exchange Commission has opened an informal inquiry into the company's clinical trials for its prostate cancer drug, Provenge.

The inquiry comes on the heels of the U.S. Food and Drug Administration seeking more information from the company on the drug, a move that prompted a handful of shareholder lawsuits.

In a filing with the SEC Tuesday, Dendreon said that the New York Regional Office of the SEC notified the company on Monday that it was...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.